The FDA approves a new type of schizophrenia drug

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

FDA approves new obesity drug

FDA Academy - Food and Drug Administration

Compliance Training 101: All You Wanted to Know

The Ultimate Guide to Compliance Training for Employees

FDA unveils drugs to receive expedited review in support of 'national priorities'

Rare Disease Research Advocates Testify on the Impact of FDA Regulation